Similarly, the incidence of other stroke‐associated comorbidities such as diabetes mellitus and dementia is known to be reduced by anti‐TNF‐α and anti‐IL‐1β therapy in patients with rheumatoid arthritis and comorbid type‐2 diabetes (Chou et al, 2016) (Burska et al, 2015). This evidence concerns the gene IL1B and diabetes mellitus.